Becton, Dickinson and Company $BDX Stock: Turtle Creek Wealth Advisors LLC Raises Holdings

Key Points

• Turtle Creek Wealth Advisors increased its BDX stake by 248.1% in the third quarter, bringing its holdings to 10,012 shares valued at approximately $1.79 million. Institutional investors collectively own 86.97% of the company.
• Analyst sentiment remains mixed, with seven Buy ratings, nine Holds and one Sell rating; MarketBeat lists an overall Hold rating and an average price target of $185.07.
• BDX shares recently traded at $192.47, near their 52-week high, after the company beat quarterly earnings and revenue estimates. The company also pays a quarterly dividend of $1.05 per share, equating to a 2.2% yield.

Turtle Creek Wealth Advisors LLC boosted its stake in Becton, Dickinson and Company (NYSE:BDX - Free Report) by 248.1% during the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 10,012 shares of the medical instruments supplier's stock after buying an additional 7,136 shares during the quarter. Turtle Creek Wealth Advisors LLC's holdings in Becton, Dickinson and Company were worth $1,792,000 as of its most recent filing with the SEC.

Other hedge funds also recently bought and sold shares of the company. SHP Wealth Management acquired a new position in Becton, Dickinson and Company in the 4th quarter valued at about $26,000. Meeder Asset Management Inc. boosted its stake in shares of Becton, Dickinson and Company by 152.2% during the 1st quarter. Meeder Asset Management Inc. now owns 169 shares of the medical instruments supplier's stock worth $27,000 after purchasing an additional 102 shares during the last quarter. Main Street Group LTD purchased a new stake in shares of Becton, Dickinson and Company during the first quarter worth about $29,000. Bell Investment Advisors Inc acquired a new position in shares of Becton, Dickinson and Company in the second quarter valued at approximately $29,000. Finally, Kelleher Financial Advisors acquired a new position in shares of Becton, Dickinson and Company in the second quarter valued at approximately $30,000. Hedge funds and other institutional investors own 86.97% of the company's stock.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on BDX. UBS Group assumed coverage on shares of Becton, Dickinson and Company in a research report on Tuesday, July 28th. They set a "buy" rating and a $190.00 target price on the stock. Wells Fargo & Company boosted their price target on Becton, Dickinson and Company from $161.00 to $170.00 and gave the company an "equal weight" rating in a report on Friday, August 7th. Citigroup reissued a "buy" rating on shares of Becton, Dickinson and Company in a research note on Thursday, August 13th. Piper Sandler lifted their price objective on Becton, Dickinson and Company from $161.00 to $175.00 and gave the company a "neutral" rating in a research report on Friday, August 7th. Finally, Evercore set a $180.00 target price on Becton, Dickinson and Company in a research note on Monday, July 6th. Seven analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of "Hold" and an average price target of $185.07.

Insider Buying and Selling

In related news, EVP Roland Goette sold 2,438 shares of the stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $180.84, for a total value of $440,887.92. Following the completion of the sale, the executive vice president directly owned 14,856 shares in the company, valued at approximately $2,686,559.04. This represents a 14.10% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Thomas Polen, Jr. sold 4,152 shares of the business's stock in a transaction dated Thursday, August 13th. The stock was sold at an average price of $185.00, for a total value of $768,120.00. Following the transaction, the chief executive officer owned 110,163 shares in the company, valued at approximately $20,380,155. This represents a 3.63% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 6,906 shares of company stock valued at $1,265,855. Company insiders own 0.40% of the company's stock.

Becton, Dickinson and Company Trading Up 1.9%

Shares of Becton, Dickinson and Company stock traded up $3.58 during trading hours on Thursday, reaching $192.47. The stock had a trading volume of 757,070 shares, compared to its average volume of 2,469,516. The company has a current ratio of 0.87, a quick ratio of 0.51 and a debt-to-equity ratio of 0.55. Becton, Dickinson and Company has a 1 year low of $127.59 and a 1 year high of $193.67. The firm has a market capitalization of $53.03 billion, a price-to-earnings ratio of 57.97, a P/E/G ratio of 12.63 and a beta of 0.21. The firm has a 50 day simple moving average of $183.41 and a two-hundred day simple moving average of $163.23.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last posted its earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.14 by $0.09. The firm had revenue of $4.98 billion during the quarter, compared to the consensus estimate of $4.89 billion. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. The company's revenue was up 5.4% on a year-over-year basis. During the same quarter in the prior year, the company earned $3.68 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. As a group, equities research analysts anticipate that Becton, Dickinson and Company will post 12.67 earnings per share for the current year.

Becton, Dickinson and Company Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, September 30th. Investors of record on Wednesday, September 9th were issued a dividend of $1.05 per share. The ex-dividend date was Wednesday, September 9th. This represents a $4.20 annualized dividend and a dividend yield of 2.2%. Becton, Dickinson and Company's payout ratio is presently 126.51%.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company, doing business as BD, is a global medical technology company that develops, manufactures and sells devices, diagnostic products and solutions for healthcare providers, researchers and patients. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, the company serves customers in hospitals, laboratories, physician offices, pharmacies and other healthcare settings worldwide.

BD's Medical segment offers products used for medication delivery and management, including needles, syringes, infusion systems, medication preparation and dispensing technologies, and systems designed to help improve medication safety.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.